Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its lead program, paxalisib, has been awarded Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.
https://finance.yahoo.com/news/kazias-paxalisib-receives-fast-track-110000913.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.